{"abstract":"The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for fibromyalgia. Patient-Focused Drug Development is part of FDA's performance commitments in the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of fibromyalgia on daily life as well as the available therapies for fibromyalgia.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/09/23/2013-23019.html","cfr_references":[],"citation":"78 FR 58313","comment_url":null,"comments_close_on":"2013-02-10","correction_of":null,"corrections":[],"dates":"The public meeting will be held on December 10, 2013, from 1 p.m. to 5 p.m. Registration to attend the meeting must be received by November 27, 2013. See the SUPPLEMENTARY INFORMATION section for information on how to register for the meeting. Submit electronic or written comments by February 10, 2013.","disposition_notes":null,"docket_ids":["Docket No. FDA-2013-N-1041"],"dockets":[],"document_number":"2013-23019","effective_on":null,"end_page":58314,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/09/23/2013-23019.xml","html_url":"https://www.federalregister.gov/documents/2013/09/23/2013-23019/fibromyalgia-public-meeting-on-patient-focused-drug-development","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-23019?publication_date=2013-09-23","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-09-23/2013-23019/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":3170,"last_updated":"2026-07-27 16:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-09-23/pdf/2013-23019.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-23019.pdf?1379681390","publication_date":"2013-09-23","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/09/23/2013-23019.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2013-11-05T05:02:20Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":58313,"subtype":null,"title":"Fibromyalgia Public Meeting on Patient-Focused Drug Development","toc_doc":"Fibromyalgia; Patient Focused Drug Development","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":78}